Opko Health Inc (OPK)

[WiseFool]

Mizuho Securities USA Inc. Reiterates a BUY on Opko Health’s Licensee Tesaro

Mizuho Securities USA Inc.
June 19, 2015

Mizuho Securities hosted investor group meetings with CEO’s from several companies in conjunction with MSUSA’s BioPharma analyst. TSRO remained one of their favorite stocks for 2H with plenty of catalysts.

TSRO- One of our favorite stocks for 2H and beyond. Our key takes are 1) there is impressive leverage that TSRO can create from the rolapitant sales force on future oncology products, 2) we anticipate a rolapitant launch in 4Q, and after the initial inventory stocking, we expect emergence of the underlying market demand in 2H16, and 3) management reiterated a year-end analysis for the Phase III NOVA trial, with readouts on non-germline and HRD cohort, plus potentially germline cohort. We reiterate our BUY rating.

Official Report